基本信息
views: 230
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Focus of research
Pathogenetic and therapeutic aspects of chronic cholestatic and immune-mediated liver diseases
The pathophysiology of chronic cholestatic and immune-mediated liver diseases like primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, IgG4-related cholangitis and various genetic cholestatic disorders is still only partly understood. Patients may suffer from fatigue, pruritus and various other symptoms. Most of these diseases have a progressive course without adequate treatment leading to cirrosis and complications of portal hypertension. Evidence-based therapies are now available for some of these diseases such as primary biliary cholangitis, autoimmune hepatitis or IgG4-related disease, but many more efforts are needed to disclose the pathophysiological mechanisms leading to these diseases as well as the symptoms like pruritus and fatique. Using the full spectrum of laboratory techniques, ranging from basic biochemistry and in vitro cell biology to mouse models, translational studies and clinical trials with affected patients, we try to gain more insight in the pathophysiology of, and possible novel therapeutic approaches towards cholestatic and immune-mediated liver diseases.
Pathogenetic and therapeutic aspects of chronic cholestatic and immune-mediated liver diseases
The pathophysiology of chronic cholestatic and immune-mediated liver diseases like primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, IgG4-related cholangitis and various genetic cholestatic disorders is still only partly understood. Patients may suffer from fatigue, pruritus and various other symptoms. Most of these diseases have a progressive course without adequate treatment leading to cirrosis and complications of portal hypertension. Evidence-based therapies are now available for some of these diseases such as primary biliary cholangitis, autoimmune hepatitis or IgG4-related disease, but many more efforts are needed to disclose the pathophysiological mechanisms leading to these diseases as well as the symptoms like pruritus and fatique. Using the full spectrum of laboratory techniques, ranging from basic biochemistry and in vitro cell biology to mouse models, translational studies and clinical trials with affected patients, we try to gain more insight in the pathophysiology of, and possible novel therapeutic approaches towards cholestatic and immune-mediated liver diseases.
Research Interests
Papers共 526 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
GUTno. 1 (2024): 156-165
Hepatology (Baltimore, Md.)no. 1 (2024): 8-10
FRONTIERS IN IMMUNOLOGY (2024): 1251134-1251134
Francesca Colapietro,Patrick Maisonneuve,Ellina Lytvyak,Ulrich Beuers,Robert C. Verdonk,Adriaan J. van der Meer,Bart van Hoek,Sjoerd D. Kuiken,Johannes T. Brouwer,Paolo Muratori, Alessio Aghemo, Francesco Carella,
Ulrich Beuers,Tilman Sauerbruch, Gerd-Achim Kullak-Ublick, Heiner Wedemeyer, Peter Ficker,Michael Trauner
ZEITSCHRIFT FUR GASTROENTEROLOGIEno. 04 (2024): 644-646
HEPATOLOGY (2024)
Therapie-Handbuch - Gastroenterologie und Hepatologiepp.402-408, (2024)
HEPATOLOGY (2024)
Journal of hepatologyno. 3 (2024): 387-389
Roni F. Kunst,Isabelle Bolt, Rychon D. J. van Dasselaar, Bart A. Nijmeijer,Ulrich Beuers,Ronald P. J. Oude Elferink,Stan F. J. van de Graaf
JHEP REPORTSno. 1 (2024): 100917-100917
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn